1. Home
  2. GDHG vs NEUP Comparison

GDHG vs NEUP Comparison

Compare GDHG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Golden Heaven Group Holdings Ltd.

GDHG

Golden Heaven Group Holdings Ltd.

N/A

Current Price

$1.77

Market Cap

35.1M

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.43

Market Cap

28.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDHG
NEUP
Founded
2008
1996
Country
China
United States
Employees
N/A
8
Industry
Services-Misc. Amusement & Recreation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
35.1M
28.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
GDHG
NEUP
Price
$1.77
$4.43
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
4.4K
50.5K
Earning Date
07-11-2025
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$3.65
52 Week High
$8.69
$21.31

Technical Indicators

Market Signals
Indicator
GDHG
NEUP
Relative Strength Index (RSI) 40.04 34.68
Support Level $1.53 $3.91
Resistance Level $1.98 $4.56
Average True Range (ATR) 0.17 0.32
MACD -0.01 -0.09
Stochastic Oscillator 9.52 3.45

Price Performance

Historical Comparison
GDHG
NEUP

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: